1. Borker A, Choudhary N. Rituximab. Indian Pediatr.
2011; 48:627-32.
2. Phillips B, Ball C, Sackett D, Badenoch D, Straus
S, Haynes B, et al. Levels of evidence and grades of
recommendation. Available from: URL:
http://www.cebm.net/index.aspx?o=1025. Accessed on November 22nd, 2011.
3. Attiasa D, Weitzmanb S. The efficacy of rituximab
in high- grade pediatric B-cell lymphoma/leukemia: a review of available
evidence. Curr Opin Pediatr. 2008;20:17-22.
4. Griffin TC, Weitzman S, Weinstein H, Chang M,
Cairo M, Hutchison R, et al. A study of rituximab and ifosfamide,
carboplatin, and etoposide chemotherapy in children with
recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature
B-cell acute lymphoblastic leukemia: report from the Children’s Oncology
Group. Pediatr Blood Cancer. 2009;52:177-81.
5. Cairo MS, Lynch J, Harrison L, Van de ven C, Gross
T, Shiramizu B, et al. Safety, efficacy and rituximab levels
following chemoimmunotherapy (rituximab + FAB chemotherapy) in children
and adolescents with mature B- cell Non-Hodgkin lymphoma (B-NHL): a
Children’s Oncology Group report. Blood (ASH Meeting Abstracts).
2008;112:838.
6. European Medicines Agency. MabThera Product
Information. Available from: URL:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf.
Accessed November 22nd, 2011.